Linxweiler, M.; Schneider, M.; Körner, S.; Knebel, M.; Brust, L.A.; Braun, F.L.; Wemmert, S.; Wagner, M.; Hecht, M.; Schick, B.;
et al. Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation. Cancers 2024, 16, 98.
https://doi.org/10.3390/cancers16010098
AMA Style
Linxweiler M, Schneider M, Körner S, Knebel M, Brust LA, Braun FL, Wemmert S, Wagner M, Hecht M, Schick B,
et al. Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation. Cancers. 2024; 16(1):98.
https://doi.org/10.3390/cancers16010098
Chicago/Turabian Style
Linxweiler, Maximilian, Matthias Schneider, Sandrina Körner, Moritz Knebel, Lukas Alexander Brust, Felix Leon Braun, Silke Wemmert, Mathias Wagner, Markus Hecht, Bernhard Schick,
and et al. 2024. "Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation" Cancers 16, no. 1: 98.
https://doi.org/10.3390/cancers16010098
APA Style
Linxweiler, M., Schneider, M., Körner, S., Knebel, M., Brust, L. A., Braun, F. L., Wemmert, S., Wagner, M., Hecht, M., Schick, B., & Kühn, J. P.
(2024). Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation. Cancers, 16(1), 98.
https://doi.org/10.3390/cancers16010098
